Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

This study is testing a combination of two medications, neratinib and divalproex sodium, to see if they can effectively shrink advanced solid tumors. Researchers are especially interested in seeing how this combination works for cancers that have a specific genetic change called a 'RAS mutation.'

This trial is for adults with advanced solid tumors that have continued to grow after standard treatments or for which no other options exist. You may be a good fit if your cancer has a RAS genetic mutation, though there are specific health requirements regarding your ability to swallow pills and manage side effects.

Participants will take the study medications orally to see how their body reacts and to determine the safest, most effective dose. The doctors will closely monitor you for any side effects and check to see how your tumor responds to the treatment.

The study is located in Richmond, Virginia. Please note that this specific study is currently suspended, meaning it is not accepting new participants at this time.